1. Home
  2. GNLX vs EDAP Comparison

GNLX vs EDAP Comparison

Compare GNLX & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genelux Corporation

GNLX

Genelux Corporation

N/A

Current Price

$2.59

Market Cap

124.8M

Sector

Health Care

ML Signal

N/A

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

N/A

Current Price

$4.02

Market Cap

163.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNLX
EDAP
Founded
2001
1979
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
124.8M
163.4M
IPO Year
2022
1998

Fundamental Metrics

Financial Performance
Metric
GNLX
EDAP
Price
$2.59
$4.02
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
$19.75
$8.50
AVG Volume (30 Days)
135.9K
51.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
18.10
N/A
EPS
N/A
N/A
Revenue
$8,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$1.21
52 Week High
$8.54
$5.05

Technical Indicators

Market Signals
Indicator
GNLX
EDAP
Relative Strength Index (RSI) 49.36 44.76
Support Level $2.54 $3.89
Resistance Level $2.80 $4.24
Average True Range (ATR) 0.17 0.35
MACD 0.01 -0.06
Stochastic Oscillator 46.08 40.94

Price Performance

Historical Comparison
GNLX
EDAP

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: